Spyre Therapeutics transfers listing to Nasdaq Global Select Market effective Jan 19, 2024

Spyre Therapeutics, Inc.

Received approval from Nasdaq to transfer listing from Capital Market to Global Select Market.
Effective at the opening of business on January 19, 2024.
Common stock continues to trade under the symbol SYRE.
Transfer indicates the company met stricter financial requirements for higher-tier market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.